Author

Xicheng Wang

Institution: Peking University Cancer Hospital

Observed institutions: Guangdong Pharmaceutical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Peking University Cancer Hospital, First Affiliated Hospital of Guangdong Pharmaceutical University, Xuzhou Central Hospital, Xijing Hospital, Qilu Hospital of Shandong University

ORCID: 0000-0001-6073-2869

Observed ORCID: 0000-0001-6073-2869

OpenAlex ID: A5087215545

Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials

2024 · Changsong Qi, Panpan Zhang, et al. · Journal of Clinical Oncology · 62

Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial

2024 · Ziming Li, Xiaomin Dang, et al. · The Lancet Respiratory Medicine · 57

Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer

2024 · Jiachen Xu, Rui Wan, et al. · Cancer Cell · 40

Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019

2020 · Shanshan Weng, Ying Yuan, et al. · Chinese Journal of Cancer Research · 28

PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial

2025 · Yakun Wang, Jialin Lu, et al. · Signal Transduction and Targeted Therapy · 22

Neutrophil serine proteases NE and PR3 controlled by the miR-223/STAT3 axis potentiate MASH and liver fibrosis

2025 · Pengfei Zhang, Dongyang Liu, et al. · Hepatology · 15

Claudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial.

2024 · Changsong QI, Chang Liu, et al. · Journal of Clinical Oncology · 13

Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer

2023 · Qi Zhang, Jian Li, et al. · Cancer Biology and Medicine · 10

A multicenter study assessing the prevalence of germline genetic alterations in Chinese gastric-cancer patients

2021 · Yinjie Zhang, Yang Yang, et al. · Gastroenterology report · 8

Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell Carcinoma: A Multicenter, Open-label, Single-arm, phase 1b study

2025 · Hang Yang, Peng Sun, et al. · Oral Oncology · 5

Optimal choice of different neoadjuvant chemoradiotherapies for locally advanced rectal cancer: systematic review and network meta-analysis

2025 · Lian Liu, Guangyu Yao, et al. · Cancer and Metastasis Reviews · 2

Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study

2025 · Luoyan Ai, Qian Li, et al. · The Innovation · 2

Second-line raltitrexed plus irinotecan (SALIRI) with bevacizumab, cetuximab, or alone for metastatic colorectal cancer: a prospective multicenter cohort-based secondary analysis of the SALLY trial

2026 · Furong Kou, Xicheng Wang, et al. · Journal of Gastrointestinal Oncology

Clinical trial design in rare mutation tumors

2025 · Yaxuan Miao, Yi Li, et al. · Holistic Integrative Oncology

High-resolution spatial analysis reveals pregnenolone metabolism as a potential target for immuno-suppressive microenvironment of BRAF mutant colorectal cancer

2025 · Xicheng Wang, Zihao Zhao, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Works count: 16

Citation count: 321

H-index: 9

I10-index: 9